产品详细信息
- 分析方法开发、确认和验证
- 化学工艺优化、放大和验证
- 广泛的寡核苷酸化合物产品组合，包括反义寡核苷酸、适配体、复杂偶联物、发夹 RNAs、高度修饰的寡核苷酸、免疫刺激序列、miRNA、比例双链体、sgRNA、siRNA
- 产品样本
-
Accelerate Your Journey from Clinic to Market
Produce high-quality oligo APIs and efficiently advance from clinic to market, delivering therapeutics to patients with unmet medical needs
- 产品样本
- English
- 2023 年 12 月 28 日
- 3.19 MB
- 宣传单页
视频
Join Agilent at TIDES US 2024
900 Boylston St, Boston, MA 02115
Colorado Governor Polis Helps Agilent Break Ground on $725 Million Expansion of Manufacturing Operations in Frederick
Agilent leaders joined Colorado Governor Jared Polis and local government officials to break ground on $725 million investment to double manufacturing capacity of therapeutic nucleic acids in Frederick, Colorado. The investment will create more than 160 life science jobs in the area. Agilent’s manufacturing facilities in Colorado produce siRNA, antisense molecules, and CRISPR guide RNA molecules.
- 2023 年 2 月 16 日
Agilent Investing $725 Million to Expand State-of-the-Art Manufacturing Capacity for Production of Nucleic Acid-Based Therapeutics
Investment will double capacity to produce active pharmaceutical ingredients used in therapeutics for a broad range of diseases. The addition of two new manufacturing lines (known as Trains C and D) will enable Agilent to meet growing demand for siRNA, antisense and CRISPR guide RNA molecules. Agilent expects customer shipments from the expansion to begin in 2026.
- 2022 年 12 月 5 日